Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 9/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385252 | 0.79 | KCNH2 (0.43) | KCNH2KCNA5TLR7JAK2CDK2 | |
| SCHEMBL3385287 | 0.71 | PRKCI (0.51) | KCNH2KCNA5TLR7JAK2CDK2 | |
| SCHEMBL4868763 | 0.70 | KCNA5 (0.49) | KCNH2KCNA5AURKAJAK2CDK2 | |
| SCHEMBL5246200 | 0.68 | KCNH2 (0.46) | KCNH2KCNA5AURKAJAK2CDK2 | |
| SCHEMBL12188788 | 0.68 | KCNH2 (0.78) | KCNH2KCNA5JAK2CDK2TYK2 | |
| SCHEMBL4862847 | 0.67 | KCNA5 (0.48) | KCNH2KCNA5JAK2CDK2TYK2 | |
| SCHEMBL4871028 | 0.67 | AURKA (0.61) | KCNH2KCNA5AURKA | |
| SCHEMBL3382742 | 0.66 | TNF (0.70) | KCNH2KCNA5JAK2CDK2TYK2 | |
| SCHEMBL2368328 | 0.65 | KCNA5 (0.44) | KCNH2KCNA5TLR7JAK2CDK2 | |
| SCHEMBL10385937 | 0.64 | ADORA2A (0.41) | KCNH2TLR7AURKAADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456187-B2 | Furanopyrimidine compounds as potassium ion channel inhibitors | XENTION LIMITED (GB) | 2008-11-25 | — | — | US | claimed |
| EP-1758909-A1 | FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2007-03-07 | — | — | EP | claimed |
| WO-2005121149-A1 | FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2005-12-22 | — | — | WO | claimed |
| US-7456187-B2 | Furanopyrimidine compounds as potassium ion channel inhibitors | XENTION LIMITED (GB) | 2008-11-25 | — | — | US | disclosed |
| EP-1758909-A1 | FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121149-A1 | FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| US-20050282829-A1 | Furanopyrimidine compounds as potassium ion channel inhibitors | XENTION DISCOVERY LTD. (GB) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282829-A1 | Furanopyrimidine compounds as potassium ion channel inhibitors | KCNH3, HCN4, KCNH2 | KCNH2 3/4885KCNA5 6/4885TLR7 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.